Applications of magnetic resonance in model systems: Cancer therapeutics Journal Article


Authors: Evelhoch, J. L.; Gillies, R. J.; Karczmar, G. S.; Koutcher, J. A.; Maxwell, R. J.; Nalcioglu, O.; Raghunand, N.; Ronen, S. M.; Ross, B. D.; Swartz, H. M.
Article Title: Applications of magnetic resonance in model systems: Cancer therapeutics
Abstract: The lack of information regarding the metabolism and pathophysiology of individual tumors limits, in part, both the development of new anti-cancer therapies and the optimal implementation of currently available treatments. Magnetic resonance [MR, including magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and electron paramagnetic resonance (EPR)] provides a powerful tool to assess many aspects of tumor metabolism and pathophysiology. Moreover, since this information can be obtained nondestructively, pre-clinical results from cellular or animal models are often easily translated into the clinic. This review presents selected examples of how MR has been used to identify metabolic changes associated with apoptosis, detect therapeutic response prior to a change in tumor volume, optimize the combination of metabolic inhibitors with chemotherapy and/or radiation, characterize and exploit the influence of tumor pH on the effectiveness of chemotherapy, characterize tumor reoxygenation and the effects of modifiers of tumor oxygenation in individual tumors, image transgene expression and assess the efficacy of gene therapy. These examples provide an overview of several of the areas in which cellular and animal model studies using MR have contributed to our understanding of the effects of treatment on tumor metabolism and pathophysiology and the importance of tumor metabolism and pathophysiology as determinants of therapeutic response.
Keywords: clinical trial; review; fluorouracil; nonhuman; pathophysiology; paclitaxel; nuclear magnetic resonance imaging; magnetic resonance imaging; neoplasms; metabolism; animals; apoptosis; gene expression; transforming growth factor beta; oxygen; ph; cyclophosphamide; time factors; tumor necrosis factor alpha; gamma interferon; gene therapy; transgene; malignant neoplastic disease; mitomycin c; gadolinium pentetate; interleukin 1alpha; phosphate; ganciclovir; therapy; nuclear magnetic resonance; oxygenation; ceramide; lonidamine; phosphorus 31; phosphorylcholine; sphingomyelin; fluorine; electron spin resonance; combretastatin; bicarbonate; deoxyglucose; sparfosic acid; 6 aminonicotinamide; humans; human; priority journal; 6 methylthioinosine; 3 aminopropanephosphinic acid; mitoflaxone
Journal Title: NeoPlasia
Volume: 2
Issue: 1-2
ISSN: 1522-8002
Publisher: Elsevier Science Inc.  
Date Published: 2000-01-01
Start Page: 152
End Page: 165
Language: English
PUBMED: 10933074
PROVIDER: scopus
PMCID: PMC1531871
DOI: 10.1038/sj.neo.7900078
DOI/URL:
Notes: Export Date: 18 November 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jason A Koutcher
    278 Koutcher